The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Foxp3
Prostate cancer
Regulatory T cell
Targeted therapy
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
10
12
2020
revised:
10
01
2021
accepted:
18
01
2021
pubmed:
30
1
2021
medline:
8
10
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
Despite developments in the treatment of various cancers, prostate cancer is one of the deadliest diseases known to men. Systemic therapies such as androgen deprivation, chemotherapy, and radiation therapy have not been very successful in treating this disease. Numerous studies have shown that there is a direct relationship between cancer progression and inhibition of anti-tumor immune responses that can lead to progression of various malignancies, including prostate cancer. Interestingly, CD4
Identifiants
pubmed: 33513396
pii: S0024-3205(21)00117-X
doi: 10.1016/j.lfs.2021.119132
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
119132Informations de copyright
Copyright © 2021. Published by Elsevier Inc.